ESMO 2022 | Novel Von Hippel-Lindau syndrome therapies inhibiting HIF-2α

Previous efforts to develop treatments for Von Hippel-Lindau (VHL) syndrome that had targets downstream of HIF-2α were limited due to high toxicity. Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, comments on elucidating novel targets for VHL syndrome. Despite promising results from the Phase II LITESPARK-004 study (NCT03401788) of belzutifan, a HIF-2α inhibitor, a number of patients relapsed and developed resistance. Further research must be consequently conducted to develop novel therapies whilst minimizing side effects. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.